Relatively little is known about the molecular mechanisms of tumor promotion/progression in mammary carcinogenesis. Increased protein kinase C (PKC) activity is known to promote tumor formation in several tissues; however, its role in mammary carcinogenesis is not yet known. To determine if individual PKCs may selectively regulate properties of mammary tumor cells, we compared PKC isozyme levels in mammary tumor cell lines with low, moderate and high metastatic potential. All three cell lines expressed a, d, e and z PKCs; however, PKCd levels were relatively increased in the highly metastatic cells. To determine if increased PKCd could contribute to promotion/progression, we overexpressed PKCd in the low and moderately metastatic cell lines. PKCd overexpression had no signi®cant eect on growth of adherent cells, but signi®cantly increased anchorage-independent growth. Conversely, expressing the regulatory domain of PKCd (RDd), a putative PKCd inhibitory fragment, inhibited anchorage-independent growth. The ecacy of RDd as a PKCd inhibitor was demonstrated by showing that RDd selectively interfered with PKCd subcellular location and signi®cantly interfered with phosphorylation of the PKC cytoskeletal substrate, adducin. PKC-dependent phosphorylation of cytoskeletal substrate proteins, such as adducin, provides a mechanistic link between increased PKCd activity and phenotypic changes in cytoskeletaldependent processes such as migration and attachment, two processes that are relevant to metastatic potential. The reciprocal growth eects of expressing PKCd and RDd as gain and loss of function constructs, respectively, provide strong evidence that PKCd regulates processes important for anchorage-independent growth in these mammary tumor cells.
Introduction
Mammary cancer is a complicated disease process of unknown etiology. Events early in life, such as age of menarche and ®rst pregnancy, become risk determinants for development of disease decades later. These statistics emphasize that mammary cancer develops from abnormal cells that only very slowly progress to tumorigenic cells. Protein kinase C (PKC) is thought to play a major role in tumor promotion/progression in other tissues due to the fact that PKC is the major cellular receptor for tumor promoting phorbol esters (reviewed in Nishizuka, 1995; Weinstein et al., 1997) . In cultured cells, phorbol esters rapidly induce changes in cell morphology, cell ± cell communication and membrane ruing Weinstein et al., 1979) , indicating that PKC has a primary eect on the organization of cytoskeletal structures. Over a longer time course, phorbol esters also in¯uence cell growth, transformation and gene expression. These responses are mediated directly through PKC activation and also indirectly through downstream eects of PKC activation on other kinase pathways. Thus, the diversity of phorbol ester-directed responses has made it dicult to identify those responses that are directly linked to PKC activation and PKC-mediated tumor promotion. As a consequence, despite the fact that PKC activation is important for tumor promotion/progression, the critical PKC-mediated signaling events are not yet well de®ned.
PKC is actually a family of phospholipid-dependent kinases that can be divided into three categories based on in vitro activation requirements (Hug and Sarre, 1993) Conventional, calcium-dependent PKCs (a, b, g ) and novel, calcium-independent PKCs (d, e, Z, y) both require diacylglycerol (DAG) for optimal activity. Atypical PKCs (z, l) require neither calcium nor DAG. Phorbol esters, which are analogs of DAG, promote carcinogenesis by binding to and activating conventional and novel PKCs. De®ning the roles of individual PKCs in biological processes is complicated by the fact that most cells express more than one isozyme. Overexpression, knockout and inhibitor studies have all been used to evaluate the roles of individual PKCs in cell growth and to demonstrate that isozyme functions are unique rather than overlapping (reviewed in Jaken, 1997) . For example, overexpressing PKCe in normal ®broblasts increased anchorage-dependent and -independent growth, whereas overexpressing PKCa and d inhibited growth (Cacace et al., 1993; Mischak et al., 1993; Watanabe et al., 1992; Yamaguchi et al., 1995) . In contrast, overexpressing PKCa in MCF7 mammary tumor cells increased anchorage-dependent and independent growth (Ways et al., 1995) . The fact that overexpressing an individual isozyme causes dierent growth responses depending on the cell type indicates that the relationship between individual PKCs and carcinogenesis is complicated and cannot be generalized.
Another approach towards assessing the potential functional role of PKCs in carcinogenesis is to compare levels of PKCs in normal and transformed cells or tissues. The value of this approach is that reproducible dierences can be used to develop hypotheses regarding the role of individual PKCs. These hypotheses can then be tested by selectively increasing or decreasing the activity of individual PKCs. For example, PKCd levels are increased in SV40-transformed REF52 ®broblasts (Liao et al., 1994b) and NIH3T3 cells transformed with the IGF-1 receptor . In both studies, expressing dominant negative PKCd constructs inhibited anchorage-independent, but not anchorage-dependent growth. Taken together, these results demonstrate that combining information on transformation-related dierences in PKC expression levels with molecular approaches to modulate PKC isozyme activities provides a powerful experimental approach towards identifying the roles of individual PKCs in carcinogenesis.
While there is some evidence that increased PKC activity may be important in mammary carcinogenesis (Ways et al., 1995) , there is little information on the role of individual PKCs in this process. To investigate the involvement of individual PKCs in mammary tumor (MT) promotion/progression, we compared PKC isozyme levels in MT cell lines that dier in growth rate and metastatic potential. These related cell lines were originally derived from 13762NF rat mammary adenocarcinomas (Welch et al., 1983; Neri et al., 1982) . Low and moderately metastatic cell lines, MTC and MTF7, respectively, were derived from tumors growing locally in the mammary fat pad, whereas the more rapidly growing and highly metastatic MTLn3 cell line was derived from lung metastases. We found that PKCd levels were selectively increased in the more rapidly growing and highly metastatic MTLn3 cells. To establish functional correlates of the increased PKCd, we constructed cell lines from the low and moderately metastatic MT cells in which we could induce expression of PKCd. To complement this approach and to evaluate the use of PKC dominant negative constructs, we also constructed lines that express a dominant negative regulatory domain fragment, RDd. Our results demonstrate that PKCd does not directly regulate growth of MT cells; however, PKCd is involved in regulating attachment and anchorage-independence, two processes that may be directly related to the increased metastatic potential of these cells.
Results

PKC protein levels
To identify changes in PKC isozyme expression that may provide insight into the role of individual PKCs in MT growth and metastasis, we compared PKC isozyme contents in the low (L), moderate (M) and highly (H) metastatic MT cells (Figure 1 ). Immunoblots of cell lysates were stained with isozyme-selective antibodies and immunoreactive bands were quantitated by densitometry. All three cell lines express PKCs a, d, e and z; however, the isozyme expression pattern among the cell lines was dierent. We did not detect signi®cant levels of PKCb1, PKCb2 or PKCZ in these MT cells. PKCa levels were similar in cells with low, moderate or high metastatic potential. PKCe levels increased in the moderately metastatic cells compared with the low or highly metastatic cells, a pattern which does not suggest a consistent change associated with increased growth or metastatic potential. In contrast, PKCd and z levels increased signi®cantly in the highly metastatic cells relative to the less metastatic cells (Figure 1 ). PKCd levels were increased 3.1-fold and PKCz levels were increased 2.9-fold (P50.05 by Student's t-test). In addition to the increased content, the electrophoretic mobility of PKCd was retarded. Decreased electrophoretic mobility has been associated with increased phosphorylation and activation of PKCd .
PKC message levels
Cellular PKC protein levels can be upregulated by transcriptional activation or downregulated as a consequence of proteolysis associated with prolonged activation (reviewed in Hug and Sarre, 1993) . To determine if the changes in PKC protein levels correlated with changes in message levels, we quantitated PKC mRNA levels in the three cell lines (Figure 2 ). PKCa message levels were similar among Figure 1 Comparison of PKC protein levels. Cell lysates were prepared from rat MT cells with low (L), moderate (M) or high (H) metastatic potential as described in Materials and methods. Aliquots of cell extracts (50 mg) were separated on 7.5% acrylamide gels by SDS ± PAGE and transferred to nitrocellulose. Blots were stained with the isozyme-speci®c antibodies indicated on the right. Molecular weight standards in kiloDaltons (kDa) are shown on the left. These results are representative of three independent experiments the three lines. PKCe levels were selectively increased in the moderately metastatic cells. Thus, PKCa and PKCe message levels correlated with the relative protein levels and did not change with increasing growth and/or metastatic potential. PKCz message levels were very low in all three cell lines, but did appear to increase in the highly metastatic cells (data not shown). PKCd levels increased 2.3-fold in the highly metastatic cells (Figure 2c ). The corresponding increases in protein and message levels indicate that the increase in PKCd protein is due to increased transcriptional activity.
MT cell lines with increased or decreased PKCd activity
The increased PKCd and PKCz levels in the rapidly growing, highly metastatic MTLn3 cells suggested that PKCd and/or PKCz may play a functional role in the metastatic phenotype of MT cells. The current studies focused on the potential role of PKCd; the potential role of PKCz will be addressed in future studies. To determine if increased PKCd promoted MT cell growth and metastatic potential, we prepared low (L) and moderately (M) metastatic MT cell lines that stably express wild type d (wtd) (L-wtd and M-wtd, respectively). As a complementary approach towards evaluating PKCd functions, we also expressed the dominant negative regulatory domain of PKCd (RDd) in the same cells (L-RDd and M-RDd cells, respectively). These cells were used to determine if inhibiting PKCd interferes with growth and/or metastatic potential. Both constructs were epitope tagged and expressed from a zinc-inducible sheep metallothionein promoter. Clones were selected by limiting dilution, and only clones with zinc-inducible protein expression were used in these studies (data not shown). Induction was dose-dependent and zinc was not toxic at the concentrations used for induction of transgenes. Cell lines transfected with the empty plasmid pMTH 3 (Lvector, M-vector) were used to control for potential nonspeci®c eects of zinc. Induction of wtd or RDd constructs did not alter the expression levels of endogenous PKC isozymes relative to the levels expressed in vector control cells (data not shown). Furthermore, RDd did not in¯uence the basal or phorbol ester-stimulated tyrosine phosphorylation status of endogenous PKCd (data not shown), a response that has been associated with regulation of PKCd catalytic activity (Li et al., 1994; Denning et al., 1996) RDd expression selectively in¯uences endogenous PKCd subcellular location Overexpression of inactive kinase constructs has also been used as a dominant negative approach; however, in our hands these constructs do not properly localize. This may be related to the absence of autophosphorylation of C-terminal sites that regulate subcellular location, stability and/or interactions with other proteins (Bornancin and Parker, 1997; Edwards et al., 1999) . As an alternative approach, our laboratory and others have expressed PKC RDs as PKC inhibitors (Kahn et al., 1994) . RDs contain the autoinhibitory pseudosubstrate motif and could potentially interfere with endogenous PKC activities by directly inhibiting catalytic activity. RDs have also been shown to interact with binding proteins and substrates that target PKCs to appropriate subcellular locations (Mochly-Rosen and Gordon, 1998; Jaken, 1997; Dekker and Parker, 1997) . Thus, RDs may also inhibit by competing for endogenous PKC binding to intracellular binding proteins. Although there is good rationale for using RDs as PKC inhibitors, direct evidence that they interfere with endogenous isozymes and inhibit substrate phosphorylation have not been presented.
To determine if RDd was compartmentalized the same as endogenous PKCd, we compared partitioning of PKCd and RDd between soluble and particulate subcellular fractions. Whereas endogenous PKCd was recovered in both the soluble and particulate fractions of M-vector and M-RDd MT cells, RDd was exclusively recovered in the particulate fraction ( Figure 3a) . Similar results were found with the LRDd MT cells (data not shown). Thus, RDd is properly positioned to interfere with membraneassociated PKC functions.
To determine if membrane associated RDd influenced the membrane localization of endogenous PKCs, we compared the levels of PKC isozymes in the particulate and soluble fractions of vector control Figure 2 Comparison of PKC mRNA levels. Total RNA was prepared from mammary adenocarcinoma cells with low (L), moderate (M) and high (H) metastatic potential and hybridized with PKC isozyme-speci®c riboprobes in ribonuclease protection assays as described in Materials and methods. For PKCa (a) and PKCe (c), 25 mg RNA was hybridized with probe and the sizes of the protected fragments, 360 bp and 160 bp respectively, are indicated on the right. For PKCd (b), 10 mg RNA was hybridized with d-probe and the size of the protected fragment was 279 bp. Controls include the isozyme-speci®c riboprobe alone (®rst lane) and the riboprobe hybridized with tRNA (second lane). The autoradiographs shown were exposed 6 h (a and b) or 18 h (c). Similar results were obtained with three dierent RNA preparations for each cell line and RDd expressing cells. Blots of soluble and particulate fractions from vector control and RDd expressing clones of L and M metastatic parental lines were probed with antibodies to PKCs a, d and e. Relative levels of PKC isozymes were quantitated by densitometry and are reported in Figure 3b . In L-and M-vector control cells, particulate:soluble ratios of PKCd were 1.2 and 1.8, respectively. Zinc-induced expression of RDd consistently decreased the particulate : soluble ratio of endogenous PKCd to 0.4 ± 0.8. In contrast, RDd did not aect the particulate : soluble ratios of PKCs a or e . These results indicate that RDd selectively interferes with membrane localization of PKCd and not other endogenous PKCs.
The eect of RDd on endogenous PKCd localization was also monitored by immuno¯uorescence. In M-wtd cells, both endogenous and exogenous (HA-tagged) PKCd are diusely distributed throughout the cytoplasm and concentrated in the perinuclear region (Figure 4, top) . PKCd is not directly associated with nuclei since PKCd was not detected on immunoblots of puri®ed MT cell nuclei (data not shown). In contrast to the predominant PKCd cytoplasmic staining, RDd is concentrated in the cell perimeter (Figure 4 , bottom left), consistent with the biochemical partitioning of RDd into the particulate fraction. RDd expression in¯uenced the endogenous PKCd immunostaining pattern. In the absence of RDd, PKCd staining extends beyond the perinuclear region to the cell edges. However, in cells expressing RDd, PKCd staining in cell perimeters is reduced. As a result, endogenous PKCd appears to be constricted to the perinuclear region (Figure 4 , bottom right). These data are consistent with the subcellular fractionation data showing that RDd displaces endogenous PKCd from ) . In other studies, we found that PKCd and RDd did not aect levels of phosphorylated MAP kinase, a response that directly correlates with mitogenic activity in a variety of cells (data not shown). Induced expression of RDd caused a small but signi®cant decrease in saturation density from 2.3610 5 to 1.6610 5 cells/cm 2 for both M-RDd clones 5 and 41. These results suggest that although RDd does not directly in¯uence growth rate, it may indirectly aect saturation density by disrupting other cell functions.
The eects of exogenous PKCd and RDd expression on anchorage-dependent clonal growth were also assessed. In the absence of zinc, the numbers of vector control, L-RDd and M-RDd colonies were similar (Table 1) . Zinc did not in¯uence clonogenic growth of the vector control cells; however, zinc dramatically decreased both the size and number of L-RDd and M-RDd colonies (Table 1) . Since zinc induction did not signi®cantly in¯uence cell doubling times (Figure 6 ), decreased colony size may be indirectly related to decreased survival and/or attachment.
Eects of PKCd and RDd transgene expression on clonogenic growth in soft agar
Progression of tumorigenic cells toward a metastatic phenotype is often accompanied by increased anchorage-independent growth and decreased requirements for cell-substratum adhesion. To determine if PKCd could promote the anchorage-independent phenotype, we assayed growth of M-wtd and M-RDd cells in soft agar in the presence and absence of zinc. Zinc did not aect the number or size of colonies formed from Mvector control cells (Table 2) . However, zinc-induced wtd expression increased the number of anchorageindependent colonies by 60% in both clones tested (Table 2) . Conversely, zinc-induced RDd expression reduced the number of colonies by approximately 60% Figure 5 Eect of wtPKCd and RDd expression on MT cell growth. Cells were cultured in the absence or presence of zinc as described in Materials and methods. Data shown for clone Mwtd8 and clone M-RDd5 are representative of data accumulated for the other M-wtd and M-RDd MT cell clones (Table 2 ). Decreased size of the colonies was also apparent. These results demonstrate a reciprocal relationship between increased and decreased PKCd activity levels and anchorage-independent MT cell growth, thus providing strong evidence for a functional role of PKCd.
Eects of wtd and RDd transgene expression on cell attachment
The eects of RDd expression on saturation density (Figure 5 ), anchorage-dependent and anchorage-independent clonal growth (Tables 1 and 2 ) could all potentially result from RDd interfering with cell attachment. We therefore monitored the eects of exogenous PKCd and RDd expression on moderately metastatic MTF7 cell attachment. Zinc slightly reduced the rate of attachment of M-vector and M-wtd clones to the same extent, indicating that this small zinc eect is not due to zinc-induced wtd expression (Figure 6 ). In contrast, zinc reduced M-RDd attachment by 50 ± 60% compared to uninduced and M-vector cells. Decreased attachment of the M-RDd cells could account for the decreases in saturation density and clonogenic growth also noted for these cells. Since RDd has no eect on cell doubling rates, the observed decreases appear to be due to indirect rather than direct eects of RDd on cell cycle progression and growth.
PKCd phosphorylates the cytoskeletal protein adducin
The eects of modulating PKCd activity on anchorageindependent growth and attachment indicate that PKCd regulates phosphorylation of substrates involved in cell-substratum adhesion. To assess the activity of PKCd in situ, we monitored eects of expressing PKCd and RDd on phosphorylation of the endogenous cytoskeletal PKC substrates, a-and gadducin. Adducins are barbed end actin capping proteins in the cortical membrane cytoskeleton . PKC phosphorylation decreases their actincapping activity, which permits ®lament elongation and membrane protrusion, i.e. processes that occur during cell attachment and spreading. Adducin phosphorylated by PKC was monitored with a phosphorylation state selective antibody raised against a g-adducin phosphopeptide containing the PKC phosphorylation site at ser660 (Fowler et al., 1998a,b) . This antibody recognizes g-adducin phosphorylated at ser660 and aadducin phosphorylated at the homologous site at ser729 (Fowler et al., 1998a; Dong et al., 1995) . Immuno¯uorescence studies demonstrated two pools of pSer660-adducin, perinuclear cytoplasmic and peripheral. Pser660-adducin accumulated in the peripheries of attaching MT cells, indicating that attachment stimulated adducin phosphorylation in this region (Figure 7a,b) . Zinc treatment of M-wtd cells to induce PKCd expression increased cytoplasmic and peripheral PKCd staining (Figure 7h) . A corresponding increase in adducin phosphorylation (both cytoplasmic and peripheral) was also observed by immuno¯uorescence (Figure 7d,f) and by immunoblot (Figure 8) . PKCd expression stimulated a-adducin and g-adducin phosphorylation twofold without increasing total adducin levels ( Figure 8 ). These results indicate that PKCd is an in vivo ser660 adducin kinase.
Inhibition of anchorage-independent growth and attachment by RDd expression could occur either by blocking PKCd activity throughout the cell or alternatively, by interfering only at discrete, localized sites. In contrast to PKCd, which is distributed throughout the cell, RDd is concentrated in cell (Figure 7g ), which suggests that RDd inhibition may be localized to this region. If RDd inhibited PKCd activity throughout the cell, then RDd expression should cause a general decrease in cellular pSer660-adducin in both peripheral and cytoplasmic compartments. However, immunoblots of cell extracts prepared from RDd cells with or without zinc treatment demonstrated that RDd did not significantly decrease the total pSer660-adducin content (data not shown). On the other hand, immuno¯uorescence staining showed that RDd expression selectively decreased pSer660-adducin staining in cell peripheries of attaching cells, but had little eect on cytoplasmic staining (Figure 7c,e) . These data are consistent with the notion that the selective localization of RDd to the periphery results in selective inhibition of adducin phosphorylation in this region. When considered in context with the inhibition of cell attachment (Figure  6 ), the results indicate that RDd in the cell periphery inhibits phosphorylation of PKC substrates in this region (e.g., adducin). Interfering with phosphorylation in the cell periphery could potentially interfere with cell attachment.
Discussion
Progression of normal cells to tumor cells requires a series of genetic and epigenetic events that result in changes in growth, gene expression, morphology and invasive properties. Since PKC has been linked to tumor promotion/progression in other tissues, we sought to identify changes in PKC isozyme expression that are functionally linked to increased growth and metastatic potential of MT cells. We found that PKCd levels were selectively increased in highly metastatic MT cells relative to less metastatic, related cell lines. Through experimentation with gain and loss of function PKCd constructs, we found that PKCd does not directly in¯uence anchorage-dependent growth and progression through the cell cycle. On the other hand, expressing PKCd enhanced and expressing RDd inhibited anchorage-independent growth. Expressing RDd also interfered with cell attachment and locally interfered with phosphorylation of the membrane skeletal protein adducin in cell peripheries. Thus, localized inhibition of membrane skeletal protein phosphorylation provides a mechanistic link between RDd expression and inhibition of attachment and anchorage-independent growth, processes that are likely to in¯uence the metastatic potential of tumor cells in vivo.
An important key to understanding the role of individual PKCs in physiological processes is to identify substrate proteins and determine how PKC phosphorylation modi®es their functions. We have isolated a group of PKC substrates by screening expression libraries for PKC interacting proteins (Chapline et al., 1993) . These PKC binding proteins/ (7) or presence (+) of zinc for 24 h were detached with trypsin and replated onto coverslips. After 1 h, cells were ®xed and stained with HA (g,h) or pSer660-adducin (a ± f) antibodies as described in Materials and methods. Photographs were taken with a 663 objective lens and represent two independent experiments Figure 8 Eect of wtPKCd expression on steady state adducin phosphorylation. Cell lysates were prepared from MTF7 (M) vector control and wtd clones that were cultured in the absence (7) or presence (+) of zinc for 24 h. Cell extracts were electrophoresed, blotted and stained with the adducin antibodies indicated on the left. Arrowheads (right) indicate a-and gadducins. Results are representative of two independent experiments substrates are named STICKs for Substrates That Interact with C-Kinase. Many proteins identi®ed as STICKs, such as MARCKs, MacMARCKs and adducins (reviewed in Jaken, 1997) , are actin binding proteins that participate in the organization of actin cytoskeletal structures. Binding to and phosphorylating cytoskeletal-associated proteins suggests a means by which PKC activity can directly regulate cytoskeletaldependent processes. We showed that PKCd overexpression increased phosphorylation of adducin at ser660 and that RDd selectively decreased pSer660-adducin staining in the outer edge of attaching cells where RDd is also concentrated. Although decreased peripheral adducin kinase activity correlated with reduced attachment eciency, our studies do not yet directly address the role of adducin itself in cell attachment and cytoskeletal remodeling. Presumably, PKCd and RDd expression would modulate the phosphorylation of other membrane skeleton PKCd substrates in addition to adducin. Nonetheless, our data suggest that modulating PKCd activity levels coordinately modulates the phosphorylation state and function of adducins and possibly other cytoskeletal proteins that are also involved in cell attachment.
Functional eects of expressed RDs as PKC inhibitors have been previously demonstrated (Liao et al., 1994b; Kahn et al., 1994) , although the mechanism of in vivo inhibition has not been clari®ed. In vitro studies indicate that RD inhibition is at least partially due to the N-terminal autoinhibitory pseudosubstrate sequence (Parissenti et al., 1998) . However, since RDs are approximately 1000-fold more potent than the 11 amino acid pseudosubstrate peptide at inhibiting PKC activity in vitro, pseudosubstrate inhibition is only part of the mechanism (Chapline et al., manuscript in preparation) . A second component involves direct interactions between RDs and PKC binding proteins such as STICKs and RACKs (Jaken, 1997; MochlyRosen and Gordon, 1998) . In fact, RDd directly binds STICKs and competes for holoenzyme PKC-STICK interactions in in vitro assays (Liao et al., 1994a; Chapline et al., manuscript in preparation) . While these in vitro assays demonstrate the potential utility of RDs as dominant negatives, additional studies were needed to demonstrate that RDd in¯uenced endogenous PKCd location and inhibited substrate phosphorylation in vivo. First, we demonstrated that RDd selectively partitioned into the membrane fraction, a localization that is consistent with its phospholipid and/or protein binding properties. It is important to note that active PKCd and RDd were both concentrated in cell peripheries, which indicates that RDd is appropriately localized to interfere with endogenous PKCd activities. Second, we showed that RDd inhibited phosphorylation of a known PKC substrate, adducin. Inhibition was localized to cell peripheries, consistent with the concentration of RDd in this region. Third, we showed that RDd expression selectively interfered with membrane-association of PKCd compared to other PKCs expressed in these cells which indicates that RDd selectively interferes with PKCd activity. In more recent studies, we found that expressing RDe in MT cells produces a dierent phenotype (data not shown), indicating that RDs of dierent isoforms produce dierent eects, a result that is consistent with isozyme-selective inhibitory activity. Additional information on PKCd selective binding proteins is needed to fully evaluate the mechanism of RDd inhibition. Although our studies focused on STICKs, several other categories of PKC binding proteins, some of which are isozyme selective, have been identi®ed. These potential targeting proteins include RACKs, PICKs, PH domain proteins, InaD and others (reviewed in Jaken, 1997; Mochly-Rosen and Gordon, 1998 ) (see also Wu et al., 1998; Van Huizen et al., 1998; Yao et al., 1994) . Regardless of the mechanism, our studies provide convincing evidence that RDd selectively interferes with signaling through PKCd pathways.
Several studies have used expression of PKCd or dominant negative constructs to evaluate the role of PKCd in growth and transformation. In some cells, increased PKCd activity was associated with increased growth and transformation. For example, expressing PKCd dominant negative constructs interfered with increased growth of c-sis, IGF-1R and SV40-transformed ®broblasts (Li et al., 1996) . Thus, comparable to results with the MT cells, downregulating endogenous PKCd activity interfered with transformation. In MT cells as well as c-sis and IGF-I receptor transformed ®broblasts, increased PKCd expression did not in¯uence adherent cell growth but did enhance anchorage-independent growth . Growth inhibition or enhancement by the dominant negative or active kinases, respectively, suggests that PKCd cooperates with certain oncogenes to promote transformation. However, it must be noted that PKCd activity was associated with growth inhibition of other cells. PKCd overexpression inhibited growth of normal ®broblasts (Mischak et al., 1993) , and in one study, expressing a catalytically inactive PKCd promoted transformation by c-src (Lu et al., 1997) . These apparently con¯icting results indicate that eects of increasing or decreasing PKCd activity may be context speci®c. Nonetheless, the accumulated data indicate that in some cases increased PKCd activity in cells that are already tumorigenic, such as the MT cells used in these studies, may cooperate with other signaling pathways to increase tumorigenic potential. Increased tyrosine phosphorylation of PKCd is one mechanism by which other pathways could upregulate PKCd activity and in¯uence transformation . However, we found no eect of RDd on PKCd tyrosine phosphorylation in MT cells (data not shown). Instead, our studies point to a role for PKCd in phosphorylation of cytoskeletal substrates and regulation of cytoskeletal processes as a means of in¯uencing attachment and anchorage-independent growth.
The studies presented demonstrate that PKCd does not substantially interfere with anchorage-dependent growth of MT cells, but does regulate cell-substratum attachment and anchorage-independent growth. These processes are important in the escape of cells from the primary tumor, survival in the circulation and establishment of metastases. Other studies are in progress to directly evaluate eects of RDd expression on MT cell metastatic potential in vivo (Kiley et al., 1999) . Given the functional similarities in the metastatic process across species, it is possible that increased PKCd could also contribute to metastatic potential of human MT cells. Finally, although these studies have focused on PKCd, the increased expres-sion of PKCz protein in MTLn3 cells indicates that PKCs other than PKCd may also be involved in metastatic progression. The strategies outlined in these studies provide a framework for evaluating the potential contribution of each PKC isozyme expressed by the mammary cells in MT promotion/progression.
Materials and methods
Materials
PKCe, PKCz, PKCb1 and PKCb2 speci®c antibodies were prepared to C-terminal peptide sequences and anity-puri®ed as previously described (Schaap et al., 1989; Ways et al., 1992) . The PKCd antibody was prepared to the C-terminal 14 kDa-piece of rat PKCd expressed in E. coli. The PKCaspeci®c monoclonal antibody (M4) described previously (Leach et al., 1988) is available from Upstate Biotechnology, Inc. (Lake Placid, NY, USA). PKCZ antibody was from Transduction Laboratories. Mouse anti-HA monoclonal (clone 12CA5) antibody was from Boehringer-Mannheim (Indianapolis, IN, USA). Antibodies for a-and g-adducin have been described (Dong et al., 1995) . Rabbit anti-pSer660-adducin antiserum was raised to a phosphopepetide containing the PKC phosphorylation site in a, b and g adducins. The antiserum was anity puri®ed and shown to be phosphorylation-state selective. All other reagents were from standard commercial sources.
Cell culture
MTC (passages 24 ± 30), MTF7 (passages 16 ± 22) and MTLn3 (passages 45 ± 51) rat 13762NF mammary adenocarcinoma cell lines were grown in antibiotic-free aMEM supplemented with 5% fetal bovine serum at 378C in a humidi®ed 5% CO 2 -air atmosphere.
Sample preparation and immunoblot analysis
Cell lysates and/or subcellular soluble and particulate fractions were prepared as described (Kiley and Jaken, 1990) .
Ribonuclease protection assay
Riboprobes (antisense RNA) were synthesized from rat PKC cDNA restriction fragments in the presence of [a 32 P]UTP using MAXIscript TM in vitro transcription kit from Ambion, Inc. (Austin, TX, USA). The DNA restriction fragments used for PKCs a, d, and e have been described (Liao et al., 1994b) . All buers and enzymes were provided in the RPAII TM ribonuclease protection assay kit from Ambion, Inc. (Austin, TX, USA).
